Lopinavir/Ritonavir Pharmacokinetics in HIV/HCV-Coinfected Patients with or Without cirrhosis

Therapeutic Drug Monitoring

Volumn 30, Issue 3, 2008, Pages 306-313

  Micheli, Valeria ^a   Regazzi, Mario ^b   Dickinson, Laura ^c   Meraviglia, Paola ^a   Villani, Paola ^b   Khoo, Saye H ^c   Viganò, Paolo ^d   Cordier, Laura ^a   Cusato, Maria ^b   Duca, Piergiorgio ^e   Orlando, Giovanna ^a   Rizzardini, Giuliano ^a   Back, David J ^c   Cargnel, Antonietta ^f  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d Hospital of Legnano   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f Foundation AIDS Aiuto Aids aid   (Italy)

Author keywords

Hepatic impairment; HIV hepatitis C virus coinfection; Lopinavir ritonavir; Pharmacokinetics; Therapeutic drug monitoring; Unbound drug

Indexed keywords

DIDANOSINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; LOPINAVIR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE; RITONAVIR;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG PROTEIN BINDING; FEMALE; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KRUSKAL WALLIS TEST; LIVER CIRRHOSIS; LIVER DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORNING DOSAGE; PRIORITY JOURNAL; STEADY STATE; TANDEM MASS SPECTROMETRY; ULTRAVIOLET SPECTROSCOPY; AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; ECHOGRAPHY; LIVER FUNCTION TEST; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; RISK FACTOR; ULTRAFILTRATION; ULTRAVIOLET SPECTROPHOTOMETRY;

ADULT; AREA UNDER CURVE; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HEPATITIS C; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINONES; RISK FACTORS; RITONAVIR; SPECTROPHOTOMETRY, ULTRAVIOLET; ULTRAFILTRATION;

EID: 47249136431     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318177209e     Document Type: Article

References (36)

1. Lee LM, Karon JM, Selik R, et al. Survival after AIDS diagnosis in adolescents and adults during the treatment era, United States, 1984-1997. JAMA. 2001;285:1308-1315.
2. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA. 1998;279: 450-454.
3. Rockstroh JK, Mocroft A, Soriano V, et al. and EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis. 2005;192: 992-1002.
4. Den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus coinfection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1-infection. AIDS. 2000;14:3451-3455.
5. Sulkowski MS. Hepatotoxicity associated with antiretroviral therapy containing HIV-1 protease inhibitors. Semin Liver Dis. 2003;23:183-194.
6. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis. 2004; 38:S90-S97.
7. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. October 10, 2006. Available at: http://AIDSinfo.nih.gov. Accessed November 22, 2008.
8. Gulick RM, da Silva B, McMillan F, et al. Lopinavir/ritonavir (LPV/r)-based therapy in antiretroviral (ARV)-naïve, HIV-infected patients: 6-year follow-up of study 720 [Abstract P28]. From the proceeding of the 7th International Congress on Drug Therapy in HIV Infection, 2004.
9. Kempf DJ, King MS, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis. 2004; 189:51-60.
10. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther. 2002;7:165-174.
11. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reversetranscriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185:599-607.
12. FDA notifications. FDA approves new Kaletra formulation. AIDS Alert. 2005;20:142-143.
13. Abbott Laboratories. Kaletra. European summary of product characteristics. March 20, 2001. Maidenhead, UK: Abbott Laboratories; 2001.
14. Sham H, Kempf D, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218-3224.
15. Malavaud B, Dinh B, Bonnet E, et al. Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther. 2000;5:3-5.
16. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, et al. Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. AIDS. 2007;21:41-46.
17. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
18. De Requena DG, Jimenez-Nacher I, Soriano V. Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations. AIDS Res Hum Retroviruses. 2005;21:555-559.
19. Arribas J, Pulido F, Peng JZ, et al. Evaluation of the multiple-dose pharmacokinetics of lopinavir/ritonavir in HIV and HCV co-infected subjects with mild or moderate hepatic insufficiency [Abstract F2/6]. From the proceedings of the 9th European AIDS Conference; 2003.
20. st Inter Work on HIV and Hepatitis Coinfection; 2004.
21. Gonzalez-Requena D, Nunez M, Jimenez-Nacher I, et al. Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection. AIDS Res Hum Retroviruses. 2004;20:698-700.
22. Canta F, Marrone R, Bonora S, et al. Pharmacokinetics and hepatotoxicity of lopinavir/ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients. J Antimicrob Chemother. 2005;55:280-281.
23. Boffito M, Hoggard PG, Reynolds HE, et al. The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. Br J Clin Pharmacol. 2002;54:262-268.
24. Boffito M, Gatti G, Almond LM, et al. Amprenavir protein binding in HIV-infected patients [Abstract 4.1]. From the proceedings of the 9th European AIDS Conference; 2003.
25. Boffito M, Hoggard PG, Lindup WE, et al. Lopinavir protein binding in vivo through the 12-hour dosing interval. Ther Drug Monit. 2004;26: 35-39.
26. Almond LM, Boffito M, Hoggard PG, et al. The relationship between nevirapine plasma concentrations and abnormal liver function tests. AIDS Res Hum Retroviruses. 2004;20:716-722.
27. Almond LM, Hoggard PG, Edirisinghe D, et al. Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals. J Antimicrob Chemother. 2005;56:738-744.
28. Moyer TP, Temesgen Z, Enger R, et al. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem. 1999;45:1465-1476.
29. Dickinson L, Robinson L, Tjia J, et al. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;829:82-90.
30. Micheli V, Meraviglia P, Regazzi M, et al. Lopinavir/ritonavir administration in HIV/HCV coinfected patients: pharmacokinetic consideration. 2nd European HIV Drug Resistance Workshop. HIV Med. 2004; 5:46.
31. Regazzi M, Maserati R, Villani P, et al. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob Agents Chemother. 2005;49:643-649.
32. Cooper C, van Heeswijk RP, Bilodeau M, et al. The pharmacokinetics (PK) of single-dose and steady-state tipranavir/ritonavir (TPV/r) 500/200 mg in subjects with mild or moderate hepatic impairment [Abstract 45]. From the proceedings of the 6th Inter Work on Clinical Pharmacologic HIV Therapy; 2005.
33. Morello J, Garcia-Gascò P, Blanco F, et al. Higher plasma levels of tipranavir in patients with more significant liver fibrosis and risk of liver toxicity [Abstract 35]. From the proceedings of the 6th Inter Work on Clinical Pharmacologic HIV Therapy; 2007.
34. Moltò J, Valle M, Blanco A, et al. Exposure to Lopinavir (LPV) among HIV/HCV co-infected patients without liver function impairment [Abstract 36]. From the proceedings of the 6th Inter Work on Clinical Pharmacologic HIV Therapy; 2005.
35. Barreiro P, Rodriguez-Novoa S, Labarga P, et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis. C J Infect Dis. 2007;195:973-979.
36. Peng JZ, Pulido F, Causemaker SJ, et al. Pharmacokinetics of lopinavir/ ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment. J Infect Dis. 2006;193:37-46.